Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04833114
Status:
RECRUITING
Last Update Posted:
2023-10-12
First Post:
2021-02-10
Brief Title:
Polatuzumab Vedotin Plus Rituximab Ifosfamide Carboplatin and Etoposide Pola-R-ICE Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma DLBCL
Sponsor:
GWT-TUD GmbH
Organization:
GWT-TUD GmbH
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Relapsed Diffuse Large B-cell Lymphoma |
| Refractory Diffuse Large B-Cell Lymphoma |
Keywords: